Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

October 2013 - FRMC

Department
10/23/2013
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi® (enzalutamide) in August 2012 to treat patients with metastatic castration-resistant prostate cancer who previously failed treatment with docetaxel. The oral drug, marketed by Astellas Pharma, Inc. and Medivation,...
The FDA approved Xtandi®...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer pain maintained reductions in pain for at least 6 months, according to a review of randomized, controlled trials, single-arm, open-label trials, open-label extension trials, and epidemiologic trials.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
Department
10/23/2013

Tim Casey

Tim Casey
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer pain and opioid-induced constipation who took lubiprostone did not have an affect on opioid-induced analgesia.
Patients with chronic non-cancer...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and controlled, persistent pain had statistically significant higher mean unadjusted all-cause pharmacy costs if they had breakthrough pain. 
Peoople with cancer and...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare professionals discussed issues related to cancer-related pain during a satellite symposium titled Managing Breakthrough Pain Across the Provider Continuum. 
At the AAPM meeting, healthcare...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat patients with castrate-resistant prostate cancer, the AUA released guidelines at its annual meeting to decide what options are best for numerous sub-types of the disease. 
To help clinicians treat...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of a prospective, randomized trial found that there was no significant difference in 90-day complications after patients with bladder cancer underwent robotic radical cystectomy with extracorporeal urinary...
San Diego—An interim analysis of...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of treatment, patients with type 2 diabetes who received 100 mg or 300 mg of canagliflozin had reductions in hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), body weight and systolic blood pressure, according to...
San Diego—After 52 weeks of...
10/23/2013
First Report Managed Care
10/23/2013

Tim Casey

Tim Casey
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2 diabetes and hypertension who received 10 mg or 25 mg of empagliflozin once daily for 12 weeks had significant and clinically meaningful reductions in systolic and diastolic blood pressure, according to a phase...
San Diego—Patients with type 2...
10/23/2013
First Report Managed Care

Department

Conference Insider
10/23/2013

Tim Casey

Tim Casey
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain, MD, and co-authors published an article in Pain Medicine that examined issues related to opioids.
Five years ago, David Fishbain,...
10/23/2013
First Report Managed Care

Advertisement

Advertisement

Advertisement